Impact of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children under 15 years old in Madrid, Spain, 2007 to 2016: The HERACLES clinical surveillance study

•PCV13 effectiveness since its inclusion in the Community of Madrid in 2010.•PCV13 implementation led to the almost total disappearance of serotype 19A.•Near-elimination of serotype 19A caused disappearance of all related meningitis cases.•Near-elimination of serotype 19A caused a decrease in antibi...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2019-04, Vol.37 (16), p.2200-2207
Main Authors: Picazo, Juan J., Ruiz-Contreras, Jesús, Casado-Flores, Juan, Negreira, Sagrario, Baquero-Artigao, Fernando, Hernández-Sampelayo, Teresa, Otheo, Enrique, Amo, María del, Méndez, Cristina
Format: Article
Language:English
Subjects:
Age
Antibiotic resistance
Antibiotics
Cefotaxime
Change detection
Children
Compliance
Conjugates
Data collection
Disease
Immunization
Incidence
Invasive pneumococcal disease (IPD)
Laboratories
Meningitis
Morbidity
Mortality
PCV13
Pneumonia
Reduction
Regional Immunization Programme (RIP)
Serotype 19A
Serotypes
Streptococcus infections
Streptococcus pneumoniae
Surveillance
Vaccination
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•PCV13 effectiveness since its inclusion in the Community of Madrid in 2010.•PCV13 implementation led to the almost total disappearance of serotype 19A.•Near-elimination of serotype 19A caused disappearance of all related meningitis cases.•Near-elimination of serotype 19A caused a decrease in antibiotic resistance.•PCV13 did not cause replacement by other serotypes not covered by the vaccine. Streptococcus pneumoniae is a major cause of morbidity and mortality worldwide. Using the data from the HERACLES clinical surveillance study (2007–2016), we describe the population impact of the 13-valent pneumococcal conjugate vaccine (PVC13) on invasive pneumococcal disease (IPD) in children
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.03.015